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Concise Report
Successful mycophenolate mofetil therapy in nine patients
with idiopathic retroperitoneal fibrosis
S. Adler1,2, S. Lodermeyer1, J. Gaa3 and U. Heemann1
Objective. To assess the therapeutic benefit of mycophenolate mofetil (MMF) in retroperitoneal fibrosis (RF).
Methods. MMF 2 g/day and prednisone 1 mg/kg were initiated in nine patients with radiological (9/9) and histological verification (2/9)
of idiopathic RF. Out of nine patients, seven needed bilateral ureteral stenting due to extensive hydronephrosis.
Results. All patients experienced regression of radiological extension. Out of seven patients, five were free of ureteral catheters after a mean
of 5.6 months and two remained on stenting due to secondary stenosis. Within 6 months mean creatinine and CRP fell from 2.5 to 1.2 mg/dl
and from 4.0 to 1.4 mg/dl, respectively. MMF was discontinued after a mean of 27 months. Prednisone was tapered to zero after a mean of
7 months. Side-effects were urinary tract infections in 7/9 patients and impaired glucose tolerance in 3/9. No recurrence occurred after
withdrawal of glucocorticoids and MMF in 7/9 patients after a mean overall follow-up of 55 months (range 12–120).
Conclusions. Treatment with MMF and glucocorticoids was successful in inducing partial or complete and lasting remission in RF. The
results suggest the use of MMF as additional immunosuppressive option.
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Introduction
Idiopathic retroperitoneal fibrosis (IRF) is a rare disease with an
estimated incidence of 0.2–0.5 per 100 000, first described
by Albarran in 1905 and completely recognized by Ormond in
1948 [1, 2].
Characteristic finding is a retroperitoneal mass around the
aorta mostly extending from the renal hilus to the iliac vessels with
possible extension to extra-abdominal organs [1, 3]. The caval vein
and one or both ureters are most often involved in this process
leading to obstruction, hydronephrosis and renal insufficiency.
CT or MRI are mostly able to distinguish from lymphoma,
haemorrhage, other inflammatory processes or tumours [4].
Histological examinations show signs of an immune-mediated
origin with infiltrates of IgG4-positive plasma cells, CD20-positive
B cells and CD4- and CD45-positive T cells in the active phase,
finally leading to fibrotic replacement [5, 6]. Meanwhile IRF is
described as an autoimmune disease with questionable antigenic
induction [3].
Treatment strategy has changed from surgery to immunomo-
dulating agents like corticosteroids, cyclosporin, AZA, tamoxifen
or in part cyclosphosphamide. Their usefulness is mostly limited
by recurrence or side-effects [3, 7].
According to histology of IRF it can be useful to quickly stop
the inflammatory action by the use of glucocorticoids. In order to
then block the T- and B-cell proliferation more specifically, a
concomitant use of MMF appears to be a promising option. MMF
has shown to be effective as antilymphocytic proliferative drug.
It is clinically used in the prevention of transplant rejection and in
autoimmune diseases like lupus nephritis and vasculitides [8, 9].
The use in IRF patients was described in a few single-case reports
for initiation as well as maintenance therapy and in two recently
reported cohorts for observational periods of <10 yrs [10–14].
We describe our experiences with a combination therapy of
corticosteroids and MMF in nine patients with IRF since 1996.
Patients and methods
Between 1996 and 2005, nine patients (seven males and two
females, age at diagnosis 41–75 yrs, mean age 58.5 yrs) were
referred to our outpatient clinic with either confirmed or suspected
IRF. One patient had already been treated with a 4-month cycle of
prednisone and presented another 4 months after cessation of
therapy with the recurrence of ureteral obstruction.
All patients showed signs of systemic inflammation with either
positive CRP (maximum 13.3mg/dl, minimum 0.5mg/dl; normal
range <0.5mg/dl) or ESR (maximum 70mm/1 h) or both.
Creatinine values ranged from 12.8 to 0.8 mg/dl prior to therapy.
Thorough clinical examination and additional chest X-ray was
performed in all patients to rule out additional malignancy. Out of
nine patients, six had been treated with antihypertensive medica-
tion consisting of -blockers in two of six patients and calcium
channel blockers and diuretics in three patients; one patient was
without antihypertensive therapy. There was no history of
methyldopa, ergotamine, radiation, surgery except in one (see
subsequently) or asbestos exposure.
This case series meets and is in compliance with ethical
standards in medicine and informed consent was obtained from
all patients. For patient overview please see Table 1.
Biopsies
Histology in 2/9 patients during laparotomy ruled out malignancy
in one patient with a history of bladder cancer and an abdominal
aortic aneurysm in a second one. It showed signs of IRF with
proliferating B- and T-cell infiltrates.
Radiological diagnosis
Abdominal ultrasound showed signs of an undefined periaortic
mass. There was mild hydronephrosis in one and moderate to
severe hydronephrosis in seven patients. All patients underwent
either abdominal CT between 1996 and 2001 or MRI thereafter for
diagnosis and follow-up. It initially showed periaortic inflamma-
tory tissue beginning inferior to the renal hili and extending to the
iliac vessels with various extensions into the retroperitoneal area.
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Initial diagnosis and follow-up considered the grade of inflamma-
tion as radiological enhancement as well as the extension and
regression of RF.
Ureteral stenting
Seven patients with moderate to severe hydronephrosis underwent
bilateral double-J stenting of both their ureters. Two patients
without hydronephrosis did not need any stenting.
Medication
Pharmacological treatment consisted of oral prednisone in a
dosage of 1 mg/kg bodyweight for 2 months and was then tapered
to zero within the next 4 months to a planned overall duration of
6 months. MMF was started concomitantly in a dosage of 1 g
twice daily.
Follow-up
During therapy and after cessation of immunosuppression it
consisted of serum creatinine, blood urea nitrogen, electrolytes,
blood glucose, CRP, lipase, ALT, AST, ESR, blood smear,
urinalysis and abdominal ultrasound. Within the first 6 months
after initiation of therapy, intervals of investigation were 2 weeks,
gradually extending to every 3 months after having achieved a
stable situation. Additional CT or MRI scans were performed
every 4–6 months during therapy and every 12 months after
cessation of immunosuppression. Ureteral stents were removed
according to radiological regression of IRF extension and
reinserted in case of recurrent hydronephrosis after removal.
Results
All patients experienced regression of IRF on CT or MRI that led
to removal of ureteral catheters in five of seven stented patients
with a mean duration of 5.6 months (range 3–8). The two
remaining patients have repeatedly been stented due to recurrence
of hydronephrosis after stent removal. Patient 7 is free of his
initially mild hydronephrosis. Creatinine declined from 2.8 to
1.3mg/dl mean.
MMF treatment was discontinued after a mean of 27 months,
range 11–96 months.
Corticosteroid treatment was discontinued after a mean of
7 months, range 3–24 months. CRP declined from a mean of 5.5
(range 0.5–13.3mg/dl) to 0.8 mg/dl (range <0.5–1.8, normal
values <0.5mg/dl), ESR values declined from a mean of 36 to
9 mm/first hour.
Special patient characteristics
Patient 1 was planned for operative lateralization of her ureters
due to extreme hydronephrosis but refused surgical treatment.
With recurrent intermittent stenting and a continuous MMF
treatment her renal function remained stable with a creatinine
of 1.2 mg/dl despite a remnant kidney function of 10% on the left
side. In order to avoid surgery she refused to stop MMF for 8 yrs.
Patient 3 presented with extensive hydronephrosis and a
creatinine level of 3.6mg/dl. Under immunosuppression and
concomitant ureteral stenting he experienced a marked regression
of IRF and then stopped corticosteroids after 3 months in fear of
side-effects. He repeatedly became hydronephrotic after stent
removal and underwent surgical ureterolysis 5 months after
initiation of medical treatment with immediate postoperative relief
of hydronephrosis. MMF was continued for 2 yrs due to the fact
of a monotherapy in an extensive disease. Creatinine fell to 1.4
mg/dl.
Patient 9 underwent emergency admission to a tertiary care
centre due to abdominal pain and radiological suspicion of an
extensive abdominal aortic aneurysm. Emergency surgery the next
day did not show an aortic aneurysm. Fast-track histology
revealed signs of RF. Surgery was discontinued without any
further procedure and the patient was transferred for medical
treatment. Immunosuppression was begun after completion of
wound healing. Radiological regression of IRF is shown prior
to immunosuppression and 4 months after initiation of therapy
(Figs 1 and 2).
Side-effects
During ureteral stenting all seven patients experienced recurrent
urinary tract infections and were sufficiently treated with
antibiotics according to microbial testing. Three patients were
found to have abnormal glucose tolerance within the first
3 months. Corticosteroids were therefore reduced prior to
schedule in combination with dietary modification and part-time
oral antidiabetics. Due to unspecific upper gastroinstestinal
disturbance in one patient, MMF was given in four applications
per day and finally had to be reduced to 50%, which was well
tolerated.
No side-effects were seen with regard to the haematopoietic
system or tumour induction in the long run.
Overall follow-up ranged from 2 to 11 yrs with respect to the
time of diagnosis and from 1 to 4 yrs after cessation of
immunosuppression.
Discussion
We could demonstrate the effectiveness of MMF and corticoste-
roids in the induction and maintenance therapy of IRF in nine
patients over the last 10 yrs with minor side-effects and no case of
recurrence after cessation of therapy.
Suspecting an autoimmune-mediated disease with immunohisto-
chemistry of CD20þ B lymphocytes and some CD4þ and
CD45þ T lymphocytes, MMF in this case appears to be a specific
antiproliferative drug. As there is evidence that MMF is able to
have additional direct antifibrotic effects this explains its use in
the early phase to stop the B- and T-cell cycle as well as initiating
TABLE 1. Overview of patient characteristics
Patient Sex Age at Leading Initial Double J Duration of Radiological Histology Steroids MMF Creatinine Side-effects/
number diagnosis symptom(s) hydronephrosis stenting stenting diagnosis months months pre- and post- complications
(months) treatment (mg/dl)
1 F 57 Abdominal pain Severe Yes Ongoing CT and MRI No 24 96 1.2–1.3 UTI
2 M 61 Back pain Moderate to severe Yes 3 CT Yes 6 36 0.8–0.8 UTI
3 M 58 Malaise Severe Yes 8 CT No 3 24 4.3–1.6 UTI
4 M 55 Back pain Moderate to severe Yes 5 MRI No 4 11 1.0–0.9 UTI
5 M 41 Malaise Severe Yes Ongoing MRI No 3 24 12.8–2.6 UTI, diabetes
6 M 53 Back pain Moderate Yes 6 MRI No 8 12 2.0–1.1 UTI
7 M 74 Malaise Mild No No MRI No 6 14 0.9–1.1 None
8 F 75 Malaise Moderate to severe Yes 6 MRI No 4 12 1.2–1.2 UTI, diabetes
conjunctivitis
9 M 53 Abdominal pain None No No MRI Yes 5 12 1.1–1.1 Diabetes
F: female; M: male; UTI: urinary tract infection.
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it at any time of disease activity to reduce fibrogenesis [15].
Furthermore, we learned from organ transplantation that due to its
high immunosuppressive potency the use of MMF can lead to a
faster reduction of concomitant steroids that appears useful with
regard to Patients 5, 8 and 9 who all experienced an intermittent
diabetic situation [8].
Mean duration of MMF application in our patient group was
27 months, which is in congruence with the data from Scheel et al.
[12] taking into account Patient 1 who refused to stop MMF for
many years in fear of surgical ureterolysis. Furthermore, it seems
reasonable to continue on MMF for more than 12 months in
patients with a suspected long-standing or severe extension of
disease like in Patients 1 and 5 or in patients with MMF
monotherapy due to early corticosteroid cessation.
For an unspecific fast reduction of acute inflammation it
appears reasonable to begin MMF in combination with cortico-
steroids and reduce or even stop the steroid application after
about 3 months when MMF should have developed antiprolif-
erative potency. We would not suggest starting with corticosteroid
therapy alone. Apart from high recurrence rates, a high dosage
appears to be necessary to control inflammation that goes along
with known side-effects [16]. This is in accordance with Patient 8
who after a 4-month cycle of corticosteroids relapsed early after
cessation and experienced a diabetic situation after initiation of
combination treatment.
In retrospect, the overall dosage and duration of glucocorti-
coids might have been too high and too long in a combination
therapy with a high immunosuppressive potency. Therefore, early
reduction of glucocorticoids in a controlled and reduced
inflammational situation might be more reasonable in favour of
a longer duration of MMF where necessary.
Whether ESR and CRP levels are reliable parameters for
surveillance remains a matter of debate. Whereas Warnatz et al.
[17] could not find a good correlation of disease activity with CRP
levels but with radiology, Scheel et al. [12] demonstrated a positive
correlation of ESR as well as CRP. We could not find a reliable
course as some patients had normal CRP values despite
radiologically detectable inflammation and a good response to
immunosuppressive treatment.
With regard to the side-effects we emphasize the need for a
short duration of ureteral stenting as all stented patients
experienced urinary tract infections. In patients with mild
hydronephrosis, without elevation of creatinine a ureteral stenting
might be unneccessary like in Patient 7.
As CT and MRI are able to identify RF we suggest histology
for query cases only keeping in mind a possibly misleading
cytology of fine needle aspirates and the risk of intervention itself
[18]. A PET might be helpful in the future for differentiation and
follow-up of inflammation vs remnant scar tissue [19].
Combination with CT or MRI might verify ureteral fibrosis due
to repeated ureteral stenting and lead to surgical treatment—as
probably will become necessary in Patients 1 and 5.
A future steroid-sparing option could be the use of other anti-
inflammatory drugs for induction therapy like TNF- inhibitors
or anti-CD20 drugs. Yet for the time being, we would favour the
combination of MMF and corticosteroids as optional therapy at
any stage of IRF leaving surgery for insufficient treatment
responses or secondary distal ureteral stenoses. As our study—
like many others—is limited by the number of patients we ask for
the establishment of a multicentre-driven study protocol compar-
ing various immunosuppressive regimen to optimize therapeutic
outcome.
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